Rookie bone void fill may be best yet
BY EDITOR, SEPTEMBER 2, 2003
Here's a trick question for all you orthopods reading this newsletter.
Name the bone void fill for spinal applications with 9 years of documented clinical success, an FDA controlled randomized clinical trial and over 75,000 cases at 1,500 hospitals. Grafton? Osteofil? Nope.
Before I divulge the answer consider the case of Ichiro. Superstar in Japanese baseball. Racked up spectacular hitting and fielding stats. Joined the Seattle Mariners baseball team four years ago. Technically was a rookie. In fact, was an all-star from Day One.
Same for “NeuGraft”®. This is the oldest “new” orthopedic product we've seen in a long time. With 9 years of patient data and an actual randomized clinical trials to support management's claims NeuGraft® has the potential, we think, to go toe-to-toe with Grafton, Osteofil, Allogro, Innergro and all the various DBM products in the $300 million bone void fill market. In fact, NeuGraft® may well be brining to market THE MOST EXTENSIVE record of documented patient outcomes of any current bone void fill product.
But it's never been sold for spine applications before so it is, technically a new product. How could this be? Well, NeuGraft® is manufactured by NeuColl, the supplier of Collagraft (distributed via Zimmer) for long bone and trauma procedures. Recently NeuColl obtained the ability to market its proprietary collagen HA/TCP bone graft matrix on its own and for spine applications and, bingo, NeuGraft® was born. When combined with aspirated bone marrow, NeuGraft® delivers osteoinductive (yes, we said inductive) properties to bone void fill.
